120 related articles for article (PubMed ID: 14741289)
1. Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent.
Khire UR; Bankston D; Barbosa J; Brittelli DR; Caringal Y; Carlson R; Dumas J; Gane T; Heald SL; Hibner B; Johnson JS; Katz ME; Kennure N; Kingery-Wood J; Lee W; Liu XG; Lowinger TB; McAlexander I; Monahan MK; Natero R; Renick J; Riedl B; Rong H; Sibley RN; Smith RA; Wolanin D
Bioorg Med Chem Lett; 2004 Feb; 14(3):783-6. PubMed ID: 14741289
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.
El-Damasy AK; Lee JH; Seo SH; Cho NC; Pae AN; Keum G
Eur J Med Chem; 2016 Jun; 115():201-16. PubMed ID: 27017549
[TBL] [Abstract][Full Text] [Related]
3. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach.
Smith RA; Barbosa J; Blum CL; Bobko MA; Caringal YV; Dally R; Johnson JS; Katz ME; Kennure N; Kingery-Wood J; Lee W; Lowinger TB; Lyons J; Marsh V; Rogers DH; Swartz S; Walling T; Wild H
Bioorg Med Chem Lett; 2001 Oct; 11(20):2775-8. PubMed ID: 11591521
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.
Yang W; Chen Y; Zhou X; Gu Y; Qian W; Zhang F; Han W; Lu T; Tang W
Eur J Med Chem; 2015 Jan; 89():581-96. PubMed ID: 25462267
[TBL] [Abstract][Full Text] [Related]
5. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies.
Thaimattam R; Daga P; Rajjak SA; Banerjee R; Iqbal J
Bioorg Med Chem; 2004 Dec; 12(24):6415-25. PubMed ID: 15556759
[TBL] [Abstract][Full Text] [Related]
6. Design and discovery of small molecules targeting raf-1 kinase.
Lowinger TB; Riedl B; Dumas J; Smith RA
Curr Pharm Des; 2002; 8(25):2269-78. PubMed ID: 12369855
[TBL] [Abstract][Full Text] [Related]
7. 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.
Dumas J; Hatoum-Mokdad H; Sibley R; Riedl B; Scott WJ; Monahan MK; Lowinger TB; Brennan C; Natero R; Turner T; Johnson JS; Schoenleber R; Bhargava A; Wilhelm SM; Housley TJ; Ranges GE; Shrikhande A
Bioorg Med Chem Lett; 2000 Sep; 10(18):2051-4. PubMed ID: 10999468
[TBL] [Abstract][Full Text] [Related]
8. ω-Phthalimidoalkyl Aryl Ureas as Potent and Selective Inhibitors of Cholesterol Esterase.
Dato FM; Sheikh M; Uhl RZ; Schüller AW; Steinkrüger M; Koch P; Neudörfl JM; Gütschow M; Goldfuss B; Pietsch M
ChemMedChem; 2018 Sep; 13(17):1833-1847. PubMed ID: 30004170
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of amide and urea derivatives of benzothiazole as Raf-1 inhibitor.
Song EY; Kaur N; Park MY; Jin Y; Lee K; Kim G; Lee KY; Yang JS; Shin JH; Nam KY; No KT; Han G
Eur J Med Chem; 2008 Jul; 43(7):1519-24. PubMed ID: 18023932
[TBL] [Abstract][Full Text] [Related]
10. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.
Schroeder MC; Hamby JM; Connolly CJ; Grohar PJ; Winters RT; Barvian MR; Moore CW; Boushelle SL; Crean SM; Kraker AJ; Driscoll DL; Vincent PW; Elliott WL; Lu GH; Batley BL; Dahring TK; Major TC; Panek RL; Doherty AM; Showalter HD
J Med Chem; 2001 Jun; 44(12):1915-26. PubMed ID: 11384237
[TBL] [Abstract][Full Text] [Related]
11. N-Phenyl-N-purin-6-yl ureas: the design and synthesis of p38alpha MAP kinase inhibitors.
Wan Z; Boehm JC; Bower MJ; Kassis S; Lee JC; Zhao B; Adams JL
Bioorg Med Chem Lett; 2003 Mar; 13(6):1191-4. PubMed ID: 12643941
[TBL] [Abstract][Full Text] [Related]
12. IRAK-4 inhibitors. Part 1: a series of amides.
Buckley GM; Gowers L; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V; Fraser JL
Bioorg Med Chem Lett; 2008 Jun; 18(11):3211-4. PubMed ID: 18474425
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors.
Zhan W; Li Y; Huang W; Zhao Y; Yao Z; Yu S; Yuan S; Jiang F; Yao S; Li S
Bioorg Med Chem; 2012 Jul; 20(14):4323-9. PubMed ID: 22721924
[TBL] [Abstract][Full Text] [Related]
14. Discovery of thieno[2,3-c]pyridines as potent COT inhibitors.
George D; Friedman M; Allen H; Argiriadi M; Barberis C; Bischoff A; Clabbers A; Cusack K; Dixon R; Fix-Stenzel S; Gordon T; Janssen B; Jia Y; Moskey M; Quinn C; Salmeron JA; Wishart N; Woller K; Yu Z
Bioorg Med Chem Lett; 2008 Sep; 18(18):4952-5. PubMed ID: 18755587
[TBL] [Abstract][Full Text] [Related]
15. Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.
Li HF; Lu T; Zhu T; Jiang YJ; Rao SS; Hu LY; Xin BT; Chen YD
Eur J Med Chem; 2009 Mar; 44(3):1240-9. PubMed ID: 18947905
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents.
Lu C; Tang K; Li Y; Li P; Lin Z; Yin D; Chen X; Huang H
Eur J Med Chem; 2014 Apr; 77():351-60. PubMed ID: 24675135
[TBL] [Abstract][Full Text] [Related]
17. Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors.
Xin Z; Zhao H; Serby MD; Liu B; Liu M; Szczepankiewicz BG; Nelson LT; Smith HT; Suhar TS; Janis RS; Cao N; Camp HS; Collins CA; Sham HL; Surowy TK; Liu G
Bioorg Med Chem Lett; 2008 Aug; 18(15):4298-302. PubMed ID: 18632269
[TBL] [Abstract][Full Text] [Related]
18. Potent urea and carbamate inhibitors of soluble epoxide hydrolases.
Morisseau C; Goodrow MH; Dowdy D; Zheng J; Greene JF; Sanborn JR; Hammock BD
Proc Natl Acad Sci U S A; 1999 Aug; 96(16):8849-54. PubMed ID: 10430859
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors.
Ramurthy S; Aikawa M; Amiri P; Costales A; Hashash A; Jansen JM; Lin S; Ma S; Renhowe PA; Shafer CM; Subramanian S; Sung L; Verhagen J
Bioorg Med Chem Lett; 2011 Jun; 21(11):3286-9. PubMed ID: 21543226
[TBL] [Abstract][Full Text] [Related]
20. Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity.
Roughley SD; Browne H; Macias AT; Benwell K; Brooks T; D'Alessandro J; Daniels Z; Dugdale S; Francis G; Gibbons B; Hart T; Haymes T; Kennett G; Lightowler S; Matassova N; Mansell H; Merrett A; Misra A; Padfield A; Parsons R; Pratt R; Robertson A; Simmonite H; Tan K; Walls SB; Wong M
Bioorg Med Chem Lett; 2012 Jan; 22(2):901-6. PubMed ID: 22209458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
